# OnCo record ventana-met-sp44 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ventana-met-sp44/>
  a schema:MedicalTest ;
  onco:kind "drug" ;
  schema:identifier "ventana-met-sp44" ;
  schema:name "VENTANA MET (SP44) RxDx Assay"@en ;
  schema:description "The MET protein stain that selects people with lung cancer for telisotuzumab vedotin."@en ;
  schema:url <https://onco.cc/drugs/ventana-met-sp44/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P240037>, <https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools> ;
  onco:status "approved" ;
  onco:tag "test" ;
  onco:modality "Immunohistochemistry companion diagnostic assay (MET protein, lung tumour tissue)" ;
  schema:alternateName "VENTANA MET (SP44) RxDx Assay" ;
  onco:approval "US 2025: Companion diagnostic for telisotuzumab vedotin in NSCLC with MET protein overexpression" ;
  onco:related <https://onco.cc/biomarkers/met-overexpression/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/companion-diagnostic/>, <https://onco.cc/technologies/histopathology-ihc/> ;
  onco:targets <https://onco.cc/targets/met/> ;
  onco:drugs <https://onco.cc/drugs/telisotuzumab-vedotin/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:terms <https://onco.cc/terms/ihc/>, <https://onco.cc/terms/companion-diagnostic-term/> .